
Erasca Inc
ERASHealthcare|Biotechnology|USA
$18.53
-0.65 (-3.39%)
Tangible Book
$1.27
Analyst Estimates
annual
{
"date": [
"202612",
"202712",
"202812",
"202912",
"203012"
],
"revenue_estimate": [
null,
0.33,
1.83,
33.24,
281.81
],
"ebit_estimate": [
-314.22,
-203.05,
-253.57,
-286.46,
-128.72
],
"ebitda_estimate": [
-316,
-213.44,
-246.16,
-353.21,
-68.54
],
"net_income_estimate": [
-297.84,
-187.73,
-226.95,
-275.88,
-121.72
],
"per_share_eps_estimate": [
-0.91,
-0.57,
-0.68,
-0.78,
-0.37
],
"eps_nri_estimate": [
-0.96,
-0.56,
-0.66,
-0.78,
-0.37
],
"dividend_estimate": [
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
1.73,
2,
2.2,
null,
null
],
"pretax_income_estimate": [
-297.84,
-187.73,
-226.95,
-275.88,
-119.79
],
"operating_cash_flow_per_share_estimate": [
-0.55,
-0.32,
null,
null,
null
],
"roa_estimate": [
-70.1,
-39,
null,
null,
null
],
"roe_estimate": [
-78.93,
-33.03,
-23.32,
null,
null
],
"gross_margin_estimate": [
null,
null,
99,
95,
null
],
"operating_cash_flow_estimate": [
-168.15,
-97.84,
null,
null,
null
],
"pettm_estimate": [
0,
0,
0,
0,
0
],
"long_term_growth_rate_mean": 0,
"long_term_revenue_growth_rate_mean": "0.00",
"future_per_share_eps_estimate_growth": null,
"future_eps_nri_estimate_growth": null,
"future_revenue_estimate_growth": null,
"future_ebit_estimate_growth": null,
"future_ebitda_estimate_growth": null,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": null,
"future_pretax_income_estimate_growth": null,
"future_book_value_per_share_estimate_growth": 23.49,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": null
}
quarterly
{
"date": [
"202606",
"202609",
"202612",
"202703",
"202706",
"202709",
"202712"
],
"revenue_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"ebit_estimate": [
-39.47,
-41.88,
-45.52,
-46.03,
-49.4,
-52.8,
-57.67
],
"ebitda_estimate": [
-39.48,
-41.28,
-42.7,
-48.91,
-51.43,
-54.05,
-61.55
],
"net_income_estimate": [
-35.36,
-37.92,
-41.78,
-43.22,
-46.89,
-49.13,
-53.82
],
"per_share_eps_estimate": [
-0.11,
-0.12,
-0.13,
-0.14,
-0.14,
-0.15,
-0.16
],
"eps_nri_estimate": [
-0.11,
-0.12,
-0.13,
-0.13,
-0.14,
-0.14,
-0.15
],
"dividend_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"pretax_income_estimate": [
-34.71,
-37.09,
-39.93,
-43.22,
-46.89,
-49.13,
-53.82
],
"operating_cash_flow_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"roa_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"roe_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"gross_margin_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"operating_cash_flow_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"pettm_estimate": [
0,
0,
0,
0,
null,
null,
null
],
"long_term_growth_rate_mean": 0,
"long_term_revenue_growth_rate_mean": "0.00",
"future_per_share_eps_estimate_growth": null,
"future_eps_nri_estimate_growth": null,
"future_revenue_estimate_growth": null,
"future_ebit_estimate_growth": null,
"future_ebitda_estimate_growth": null,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": null,
"future_pretax_income_estimate_growth": null,
"future_book_value_per_share_estimate_growth": 23.49,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": null
}